Helsinn Healthcare SA: Nausea trials

The registry lists 12 Nausea studies with Helsinn Healthcare SA as lead sponsor. 1 are open to participants now and 10 have results posted.

Phase 2 2Phase 3 9No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)RecruitingNCT06904235Phase 2
• A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast CancerCompletedNCT03403712Phase 3Results posted
• PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and VomitingCompletedNCT03204279Phase 2Results posted
• An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and VomitingCompletedNCT02557035Phase 3Results posted
• A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and VomitingCompletedNCT02517021Phase 3Results posted
• Efficacy and Safety of Palonosetron Intravenous in Prevention of Chemotherapy Induced Nausea and Vomiting in Pediatric PatientsCompletedNCT01442376Phase 3Results posted
• Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsCompletedNCT01395901Phase 3Results posted
• A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01376297Phase 3Results posted
• An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01363479Phase 3Results posted
• An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and VomitingCompletedNCT01339260Phase 3Results posted
• Safety and Efficacy of Palonosetron IV to Prevent Postoperative Nausea and Vomiting in Pediatric PatientsCompletedNCT00828295Phase 3Results posted
• Efficacy Study of Ginger (Zingiber Officinale) Extract "Ginpax" to Manage Nausea in Cancer Patients Receiving High Emetogenic Treatments and Standard Anti-emetogenic TherapyCompletedNCT01887314Not applicable